At the American Diabetes Association's Scientific Sessions in New Orleans last week, drugmakers pitched doctors and investors on the idea of new shots and pills, drugs that can be taken less frequently, and new treatments beyond GLP-1s that could come with fewer side effects
Increased demand could strain supply chains, especially during the early stages of generic market entry
All cases resolved with hydration and temporary medication discontinuation
Physicians manage obesity as a chronic disease, not a short-term solution
Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial
For instance, Class I drugs like acetaminophen display reduced C max in response to delayed gastric emptying